# A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Source: https://onco.cc/trials/nct04014205/  
OnCo record `nct04014205` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Orelabrutinib in advanced solid tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., active and no longer recruiting.

## Summary

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies is a phase 1/2 interventional study registered as NCT04014205 by Beijing InnoCare Pharma Tech Co., Ltd., with 81 participants enrolled, started 2019-11-18 and due to reach its primary completion in 2026-06-30. Interventions recorded: Orelabrutinib (ICP-022).

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04014205
- Phase: 1/2
- Setting: A Phase I/II，Multicenter, Open-Label, Study of a Novel Bruton's Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients With B-Cell Malignancies
- Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
- Enrolled: 81

## Sources

- ClinicalTrials.gov NCT04014205: https://clinicaltrials.gov/study/NCT04014205

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Orelabrutinib](https://onco.cc/drugs/orelabrutinib/)

---
JSON: https://onco.cc/api/v1/entities/nct04014205.json